Insider buying is one of the most studied — and most reliable — signals in equity research. While insiders sell for many reasons (diversification, taxes, estate planning), they buy for only one: they believe the stock is going higher.
February 2026 saw notable insider buying activity across small and micro-cap names. We tracked the most significant purchases and what they might signal.
Why Insider Buying Matters
Academic research consistently shows that insider buying, particularly in small-cap stocks, predicts future outperformance. The logic is straightforward: insiders have material non-public information about their company's prospects that the market hasn't yet priced in. When a CEO drops $1M of their own money on open-market purchases, that's a stronger signal than any press release.
The signal is strongest when:
- The purchase is large relative to the insider's existing holdings
- Multiple insiders at the same company are buying simultaneously
- The company is small enough that insider buying represents meaningful percentage of daily volume
February's Standout Purchases
1. Lexicon Pharmaceuticals (LXRX) — Raymond Debbane
Position: Board Member / Major Shareholder
Transaction: Bought 100,000 shares (~$148,000) on February 20, 2026
Context: This follows a larger purchase by Invus Global Management (1.5M shares, $2M) earlier in February
When major shareholders increase their positions, it's worth noting. Debbane and Invus now control significant voting power, and their conviction at these price levels suggests they see the stock as undervalued. Lexicon has an approved heart failure drug (Inpega) with label expansion potential—the insider activity aligns with our own thesis that the market is underpricing the pipeline optionality.
2. Conduent Inc (CNDT) — CEO Harshavardhan Agadi
Position: Chief Executive Officer
Transaction: Bought 110,000 shares (~$158,000) on February 18, 2026
Context: This was Agadi's second purchase in two months, totaling 220,000 shares ($314K)
A CEO putting nearly a third of a million dollars into their own company—twice in two months—is a strong conviction signal. Conduent is a business process services company that's undergone restructuring. The insider buying suggests management sees the turnaround taking hold. The stock trades at a discount to peers on EV/EBITDA, and the CEO's purchases align with improving operational metrics.
3. Insulet Corp (PODD) — CEO Ashley McEvoy
Position: President and Chief Executive Officer
Transaction: Bought 4,300 shares (~$1.03M) on February 20, 2026
Context: One of the largest insider purchases reported in February 2026
A million-dollar purchase by a new CEO is rare. McEvoy took the helm at Insulet (maker of the Omnipod insulin management system) in late 2025. Her six-figure bet signals confidence in the company's competitive position against diabetes pump rivals like Tandem and Medtronic. While Insulet is larger than our typical coverage (mid-cap territory), the size of this purchase makes it noteworthy for understanding sector sentiment.
4. CVRX Inc (CVRX) — Mudit Jain
Position: Board Member (Johnson & Johnson representative)
Transaction: Bought 46,800 shares (~$298,000) on February 20, 2026
CVRX is a medical device company focused on neuromodulation for cardiovascular disease. The company has faced commercialization challenges, but Jain's purchase—a significant addition to his holdings—suggests the board sees a path forward. Note that J&J, which Jain represents, is a major strategic investor. This could signal confidence in upcoming clinical or commercial milestones.
5. PCB Bancorp (PCB) — Director Sang Young Lee
Position: Director
Transaction: Bought 5,000 shares (~$112,000) on February 23, 2026
Community banks often see insider buying when management believes the stock trades below book value. PCB trades at a discount to tangible book, and Lee's purchase aligns with improving net interest margin trends in the regional banking sector following rate stabilization.
The Cluster Effect
What makes insider buying especially powerful is when multiple insiders at the same company are buying simultaneously. A single purchase could be routine. Three executives buying in the same week? That's a signal.
Lexicon (LXRX) shows this cluster effect most clearly in February 2026, with multiple large purchases from both management and major shareholders. We'd flag this as the highest-conviction setup among this month's activity.
How We Use This Data
At Open Equity, insider buying is one input in our research process — not the sole driver. We look for convergence: insider buying + improving fundamentals + technical support = high-conviction idea.
The best insider buying signals come from small companies where a single executive's purchase represents a meaningful percentage of average daily volume. When the CEO of a $30M company buys $100K worth of stock, that's a much stronger signal than a $1M purchase by an executive at a $10B company.
February Takeaway
The insiders are buying. Across biotech, business services, and financials, we're seeing conviction from those with the best information. That doesn't guarantee gains—insiders can be wrong—but it does suggest that smart money sees value in small-cap equities that the broader market hasn't yet recognized.